Shareef Laith G, Khalid Shahad Sabah, Raheem Mohanad Faris, Al-Hussainy Ali Fawzi, Al-Khayyat Noor Sameer, Al Arajy Ahmed Zakaria, Noori Mustafa M, Qasim Mohammad Alameen, Jasim Hanan Hussein
Pharmacy Department, Al-Rasheed University College, Baghdad, IRQ.
Pharmacy Deparment, Al-Nukhba University, Baghdad, IRQ.
Cureus. 2024 Oct 15;16(10):e71569. doi: 10.7759/cureus.71569. eCollection 2024 Oct.
Obesity is an exacerbated public health challenge, increasing the risk of several diseases and mortality while deteriorating the quality of life. There is significant dedication to exploring obesity therapies using glucagon-like peptide-1 (GLP-1) agonists, which have shown efficacy in reducing the number of deaths and complications associated with type 2 diabetes. This research aimed to examine the recent search popularity of GLP-1 agonists using Google Trends at both national (in Iraq) and global levels. To quantify relative search volume (RSV), the total search query activity has been transformed to a percentage scale ranging from 0% to 100%. The word "Ozempic" was chosen because of its extensive coverage in social media and web/print publications pertaining to this subject matter. A comparative search was performed targeting the phrases "Wegovy," "Saxenda," and "Mounjaro" to identify a novel combination GLP-1 agonist from August 2023 to August 2024. The present study demonstrated a statistically significant difference in the RSV among the four drugs (P < 0.0001) nationally and globally. In Iraq, the highest RSV for Ozempic was documented in Duhok, followed by Sulaymaniyah and Erbil. A comparable RSV profile has been noted for Saxenda, while substantial interest in Wegovy is seen in Ninawa. Meanwhile, globally, the highest RSV for Ozempic was recorded in Canada, the United States of America, and Australia. A distinct RSV profile has been observed for Saxenda, with heightened search interest recorded in Latin America, Poland, Sweden, and Australia. By contrast, Mounjaro received search interest primarily in Greenland and the United States, while Mounjaro search interest was noted in Canada, the United States, and Australia. This study demonstrates a significant and growing public interest in GLP-1 agonists, namely, Ozempic, Saxenda, Wegovy, and Mounjaro. As the use of GLP-1 agonists for weight loss becomes more common, more knowledge, understanding, and continuous scientific research will make it more convenient to obtain the best patient outcomes.
肥胖是一项日益严峻的公共卫生挑战，它会增加多种疾病的风险和死亡率，同时降低生活质量。人们致力于探索使用胰高血糖素样肽-1（GLP-1）激动剂治疗肥胖症，这类药物已显示出在降低2型糖尿病相关死亡人数和并发症方面的疗效。本研究旨在利用谷歌趋势在国家层面（伊拉克）和全球层面考察GLP-1激动剂近期的搜索热度。为了量化相对搜索量（RSV），已将总搜索查询活动转换为从0%到100%的百分比量表。选择“Ozempic”这个词是因为它在社交媒体以及与该主题相关的网络/印刷出版物中被广泛提及。在2023年8月至2024年8月期间，针对短语“Wegovy”“Saxenda”和“Mounjaro”进行了对比搜索，以确定一种新型复方GLP-1激动剂。本研究表明，这四种药物在国家层面和全球层面的RSV均存在统计学显著差异（P < 0.0001）。在伊拉克，杜胡克记录到Ozempic的RSV最高，其次是苏莱曼尼亚和埃尔比勒。已注意到Saxenda有类似的RSV分布情况，而在尼尼微发现人们对Wegovy有浓厚兴趣。同时，在全球范围内，加拿大、美国和澳大利亚记录到Ozempic的RSV最高。已观察到Saxenda有独特的RSV分布情况，在拉丁美洲、波兰、瑞典和澳大利亚记录到搜索兴趣增加。相比之下，Mounjaro主要在格陵兰岛和美国获得搜索兴趣，而在加拿大、美国和澳大利亚也注意到对Mounjaro的搜索兴趣。本研究表明公众对GLP-1激动剂，即Ozempic、Saxenda、Wegovy和Mounjaro有着显著且不断增长的兴趣。随着使用GLP-1激动剂减肥变得更加普遍，更多的知识、理解和持续的科学研究将使获得最佳患者治疗效果变得更加便捷。
